Table 2.
Clinical outcomes and complications.
| RIPC-Group (n = 66) | control-Group (n = 66) | p-Value | |
|---|---|---|---|
| Death (from any cause) | 7 (11) | 9 (14) | 0.559 |
| Stroke/TIA | 2 (3) | 0 (0) | 0.500 |
| disabling | 2 (3) | 0 (0) | 0.500 |
| non-disabling | 0 (0) | 0 (0) | 1.000 |
| ppMI | 0 (0) | 0 (0) | 1.000 |
| Valve-embolisation | 3 (5) | 0 (0) | 0.250 |
| Conversion to surgery | 2 (3) | 0 (0) | 0.500 |
| Vascular complications | 6 (9) | 4 (6) | 0.727 |
| Major-bleeding complications | 5 (8) | 8 (12) | 0.581 |
| New arrhythmia | |||
| Atrial flutter/fibrillation | 6 (9) | 5 (8) | 1.000 |
| AV-Block I-III | 19 (29) | 16 (24) | 0.711 |
| Branch block | 20 (30) | 20 (30) | 1.000 |
| New pacemaker | 23 (34) | 20 (30) | 0.690 |
No statistically significant differences between RIPC and non-RIPC-group. Values are n (%). RIPC = remote ischemic preconditioning; TIA = transient ischemic attack; ppMI = periprocedural myocardial infarction.